COMMUNIQUÉS West-GlobeNewswire

CORRECTION - Ossur Hf : Transactions in relation to share buyback program

21/08/2017 - 16:22

This is a correction of the announcement from 16:00 21.08.2017 CEST, NO: 61/2017. Reason for the correction: Header incorrect, other information in the announcement is correct. Previous Header: Share buyback program [...]

PCI Biotech: Invitation to first half year 2017 presentation

21/08/2017 - 16:01

Oslo, 21 August 2017 - PCI Biotech invites to a presentation of the company's second quarter and first half year 2017 report on Tuesday 29 August 2017 at Oslo Cancer Cluster Innovation Park. Time: Tuesday August 29, [...]

Ossur Hf : Share buyback program completed

21/08/2017 - 16:00

Announcement from Össur hf. No. 61/2017 Reykjavík, 21 August 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program was to [...]

Novo Nordisk A/S - Share repurchase programme

21/08/2017 - 15:52

Bagsværd, Denmark, 21 August 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]

Shire plc Director and Senior Management Changes

21/08/2017 - 15:00

Shire plc Director and Senior Management Changes August 21, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) ("Shire" or the "Company"), announces changes to its Executive Committee, as it progresses its strategy to sharpen [...]

PDMR Dealing

21/08/2017 - 11:41

LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]

Navamedic ASA: Enters into partnership agreement for distribution of ELMIRON® in the Nordics

21/08/2017 - 08:00

Oslo, August 21, 2017 - Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, today announced it has entered into a long term agreement with bene-Arznemittel GmbH (bene) for the Nordic [...]

Saniona AB: Saniona's partner, Medix, initiates Phase 3 study for tesofensine in obesity

21/08/2017 - 08:00

PRESS RELEASE 21 August 2017 Saniona, a leading biotech company in the field of ion channels, today announces that Medix has recruited the first patients in the Phase 3 clinical study for tesofensine in Mexico. This [...]

Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria

21/08/2017 - 07:15

Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission KAF156 is first compound from the [...]

Novartis et Medicines for Malaria Venture lancent une étude clinique en Afrique pour KAF156, un candidat-médicament novateur contre le paludisme multirésistant

21/08/2017 - 07:15

Ce candidat-médicament pourrait s'avérer déterminant dans la lutte contre le paludisme en éliminant rapidement l'infection paludéenne, y compris les souches résistantes et en bloquant la transmission du parasite KAF156 [...]

Corbion reports transactions under its current share buyback program

21/08/2017 - 07:00

Corbion has repurchased 41,000 of its own common shares in the period from August 14, 2017 up to and including August 18, 2017 at an average price of € 25.27 per share. The consideration of the repurchase was € 1.04 [...]

Ossur Hf : Share options granted

18/08/2017 - 18:47

Announcement from Össur hf. No. 60/2017 Reykjavík, 18 August 2017 Today, Össur hf. has granted 50,000 share options to middle management. The exercise price is DKK 30.05, i.e. the Company's average share price on NASDAQ [...]

Bavarian Nordic to Host First Half 2017 Results Conference Call

18/08/2017 - 16:00

COPENHAGEN, Denmark - August 18, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2017 first half results on Friday, August 25, 2017. The management of Bavarian Nordic will host a conference call at [...]

Orion Corporation: Managers' transactions - Heikki Westerlund

18/08/2017 - 12:45

CORRECTION TO THE DISTRIBUTION ORION CORPORATION MANAGERS' TRANSACTIONS 18 th AUGUST 2017 at 13:45 EET/EEST Orion Corporation: Managers' transactions - Heikki Westerlund Correction to the distribution of the release [...]

Completion of exercise in full of overallotment option of 15%

18/08/2017 - 10:02

Company announcement - No. 38/2017 Zealand Pharma A/S has today registered a capital increase of 156,250 new shares as completion of exercise in full of overallotment option of 15% Copenhagen, August 18, 2017 - With [...]

Immunicum AB (publ): Interim Report Q2 - Corporate Update and Outlook

18/08/2017 - 08:00

Press Release 18 August 2017 Immunicum AB: Interim Report Q2 - Corporate Update and Outlook Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing an off-the-shelf immune system primer [...]

MITHRA ANNOUNCES FIRST SUBJECT COMPLETES ESTELLE® PHASE III STUDY

18/08/2017 - 07:30

MIThRA ANNOUNCES first subject completes ESTELLE® PhAse III study Estelle ® Phase III studies remain on track to report top line results in Q3 2018 and Q1 2019 in Europe/Russia and the US/Canada respectively Liège, [...]

Nicox annonce que son partenaire licencié exclusif mondial a déposé un mémoire relatif à la lettre de réponse (Complete Response Letter) pour la solution ophtalmique de latanoprostène bunod, 0,024%

18/08/2017 - 07:30

Communiqué de Presse Nicox annonce que son partenaire licencié exclusif mondial a déposé un mémoire relatif à la lettre de réponse ( Complete Response Letter ) pour la solution ophtalmique de latanoprostène bunod, 0,024 [...]

Nicox announces that its Exclusive Licensee Submits response to CRL for latanoprostene bunod ophthalmic solution, 0.024%

18/08/2017 - 07:30

Press Release Nicox announces that its Exclusive Licensee Submits response to CRL for latanoprostene bunod ophthalmic solution, 0.024% August 18, 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, [...]